The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices ...

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Cogent Biosciences said its experimental drug, called bezuclastinib, lowered the risk of tumor progression or death by 50% ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...